Full-Time

Senior Machine Learning Engineer

Updated on 9/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
AI & Machine Learning (1)
Required Skills
LLM
gRPC
Kubernetes
MLOps
Microsoft Azure
Python
GitHub Actions
Machine Learning
Java
Docker
RAG
AWS
Observability
REST APIs
LangChain
Web Development
Data Analysis
Google Cloud Platform

Get referred to Amgen

See people who can refer or advise you

Requirements
  • The candidate must have 3–5 years of experience in artificial intelligence/machine learning and enterprise software.
  • The candidate must have comprehensive knowledge of machine-learning algorithms including regression, tree-based ensembles, clustering, dimensionality reduction, time-series models, deep-learning architectures such as convolutional neural networks, recurrent neural networks, and transformers, as well as modern large-language-model and retrieval-augmented-generation techniques.
  • The candidate must have a proven track record selecting and integrating artificial-intelligence software-as-a-service or platform-as-a-service offerings and building custom machine-learning services at scale.
  • The candidate must have expert knowledge of generative-artificial-intelligence tooling, including vector databases, retrieval-augmented-generation pipelines, prompt-engineering domain-specific languages, and agent frameworks such as LangChain and Semantic Kernel.
  • The candidate must be proficient in Python and Java, containerization with Docker and Kubernetes, cloud platforms such as Amazon Web Services, Microsoft Azure, or Google Cloud Platform, and modern DevOps/MLOps tools such as GitHub Actions, Amazon Bedrock, and SageMaker Pipelines.
  • The candidate must be able to model total cost of ownership versus net present value and present trade-offs to executives.
  • The candidate must be able to manage stakeholders and translate complex technical concepts into concise, outcome-oriented narratives.
Responsibilities
  • Engineer end-to-end machine-learning pipelines covering data ingestion, feature engineering, training, hyperparameter optimization, evaluation, registration, and automated promotion using Kubeflow, SageMaker Pipelines, the OpenAI software development kit, or equivalent MLOps stacks.
  • Harden research code into production-grade microservices, package models in Docker and Kubernetes, and expose secure REST, gRPC, or event-driven APIs for downstream applications.
  • Build and maintain full-stack artificial-intelligence applications by integrating model services with lightweight user-interface components, workflow engines, or business-logic layers.
  • Optimize performance and cost at scale by selecting appropriate algorithms, applying quantization and pruning, and tuning GPU/CPU autoscaling policies to meet strict service-level agreement targets.
  • Instrument comprehensive observability, including real-time metrics, distributed tracing, drift and bias detection, and user-behavior analytics, to diagnose and improve live models and applications.
  • Embed security and responsible-artificial-intelligence controls, including data encryption, access policies, lineage tracking, explainability, and bias monitoring, in partnership with Security, Privacy, and Compliance teams.
  • Contribute reusable platform components such as feature stores, model registries, and experiment-tracking libraries, and promote best practices across squads.
  • Perform exploratory data analysis and feature ideation on complex, high-dimensional datasets to inform algorithm selection and ensure model robustness.
  • Partner with data scientists to prototype and benchmark algorithms, advise on scalability trade-offs and production readiness, and co-own model-performance key performance indicators.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $10.1 billion, and guidance rose to $38.2-$39.4 billion.
  • Repatha sales jumped 37% to $953 million, with Uplizna up 90%.
  • A federal judge blocked Colorado's Enbrel cap, preserving U.S. pricing flexibility.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026, after data manipulation findings.
  • Novartis pelacarsen failed Phase 3 in 2026, raising Amgen's olpasiran outcomes bar.
  • Colorado's Enbrel price-cap fight continues on appeal, threatening legacy cash flow through 2027.

What makes Amgen unique

  • Repatha, Evenity, Uplizna, and Tezspire diversify growth beyond Enbrel and Prolia.
  • Amgen's 7,297-patient OCEAN(a)-Outcomes gives olpasiran a large cardiovascular readout.
  • Hyderabad's Genome Valley center expands Amgen's R&D footprint with data-driven discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.